Watchlist

Watchlist
Argos Therapeutics, Inc. (ARGS)
Argos Therapeutics, Inc. (ARGS)
Argos Therapeutics' (ARGS) CEO Jeff Abbey on Q3 2016 Results - Earnings Call Transcript
Argos Therapeutics, Inc. (ARGS) Q3 2017 Earnings Conference Call November 13, 2017 08:30 AM ET Executives Jeff Abbey - President and Chief Executive Officer Charles Nicolette - Chief Scientific Officer and Vice President, Research and Development Analysts Gil Bloom - Needham …
Argos up 70% premarket on positive late-stage kidney cancer data on lead candidate Rocapuldencel-T
Nano cap Argos Therapeutics (NASDAQ: ARGS ) jumps 70% premarket on robust volume in response to its announcement of positive data from a Phase 3 clinical trial, ADAPT, assessing lead candidate Rocapuldencel-T (Roca), in combination with Pfizer's (NYSE: PFE ) SUTENT (sunitinib m…
Argos Therapeutics beats by $0.10, misses on revenue
Argos Therapeutics (NASDAQ: ARGS ): Q3 EPS of -$0.10 beats by $0.10 . Revenue of $0.05M (-66.7% Y/Y) misses by $0.05M . Shares -10.8% . Press Release More news on: Argos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Planned equity offering roundup - healthcare
Recent S-3 filings : More news on: Sensus Healthcare, Titan Pharmaceuticals, Inc., Cerus Corporation, Healthcare stocks news, Read more …
Argos Therapeutics (ARGS) Interim Analysis Of The Phase 3 Adapt Trial Evaluating Rocapuldencel - T (AGS-003) - Slideshow
The following slide deck was published by Argos Therapeutics, Inc. in conjunction with this Read more …
Stocks to watch next week
Notable earnings: AutoZone (NYSE: AZO ), Adobe (NASDAQ: ADBE ), Bed Bath & Beyond (NASDAQ: BBBY ) on September 19; General Mills (NYSE: GIS ) and Farmer Brothers (NASDAQ: FARM ) on September 20; Presidio (NASDAQ: PSDO ) and Scholastic (NASDAQ: SCHL ) on September 21; Finish Line (NASD…
Your Weekly Pharma Scoop: Valeant's CRL Resolution, Eagle Undervalued, Array Positive Results
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is starting a weekly scoop of all sorts of news, catalysts, ratings, and other actionable details for its watchlist stocks. The watchlist is available to Total Pharma Tracker subscribers . Some sections, like the catalyst d…
Argos Therapeutics beats by $0.05, revenue in-line
Argos Therapeutics (NASDAQ: ARGS ): Q2 EPS of -$0.21 beats by $0.05 . Revenue of $0.1M (-80.0% Y/Y) in-line. Press Release More news on: Argos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Argos executes private $6M capital raise via convertible note
Argos Therapeutics (NASDAQ: ARGS ) inks an agreement with investor Pharmstandard International S.A. for the direct sale of a $6M secured convertible promissory note. The transaction should close by June 21. More news on: Argos Therapeutics, Inc., Healthcare stocks news, Read more …...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline
NEW YORK , May 9, 2017 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Argos Therapeutics, Inc. ("Argos" or the "Company") (NASDAQ: ARGS) of the May 15, 2017 deadline to seek the role of lead plaintiff in a federal securities c…
Robbins Arroyo LLP Reminds Investors of Lead Plaintiff Deadline in Argos Therapeutics, Inc. (ARGS) Class Action
Shareholder rights law firm Robbins Arroyo LLP reminds investors that a class action complaint was filed against Argos Therapeutics, Inc. (NASDAQGM: ARGS) in the U.S. District Court for the Middle District of North Carolina. The complaint is brought on behalf of all purchasers of Argos sec…
Argos Therapeutics, Inc. (ARGS)